Interaction of clozapine and other antipsychotic drugs with human α1-Adrangjc receptor subtypes

Proceedings of the Western Pharmacology Society

Volumn 42, Issue , 1999, Pages 67-69

  Brooks, Karen M ^a   Cai, Jidong ^a   Sandrasagra, Anthony ^a   Roehr, Joachim E ^a   Errazo, Rowena ^a   Vargas, Hugo M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 5 METHYLURAPIDIL; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PHENTOLAMINE; PRAZOSIN; RECEPTOR SUBTYPE; RISPERIDONE; SPIPERONE;

ANIMAL CELL; BINDING AFFINITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYMPTOM; NEUROTRANSMISSION; NONHUMAN; SCHIZOPHRENIA;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CHO CELLS; CLOZAPINE; CRICETINAE; EUKARYOTIC CELLS; HUMANS; PRAZOSIN; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 0032739962     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Creese I, Burt DR & Snyder SH: Science 192:481-483 (1976).
2. Baldessarini RJ & Frankenburg FR: New England J Med 324:746-754(1991).
3. Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP & Meert TF: J Pharmacol Exp Ther 244:685-693 (1988).
4. Leysen JE, Gommeren W & Eenz A: J Pharmacol Exp Ther 247:661-670(1988).
5. Meltzer HY: Psychopharmacology 99:S18-S27 (1989).
6. Corbett R, Griffiths L, Shipley JL, Shukla U, Strupczewski JT, Szczepanik AM, Szewczak MR, Turk DT, Vargas HM & Kongsamut S: CNS Drug Reviews 3:120-147 (1997).
7. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E & Cohen BM: Brit J Psychiatry 160(suppl 17): 12-16 (1992).
8. Svensson TH, Mathe JM, Andersson BM, Nomikos GG, Hildebrand BM & Marcus M: J Clin Psychopharmacology 15 (Suppl 1):11S18S.
9. King DJ: Eur Neuropsychopharmacol 8:33-42 (1998).
10. Kafka SH, Vargas HM & Corbett R: Soc Neurosci 24:755 (1998).
11. Mathe JM, Nomikos GG, Hildebrand BM & Svensson TH: Eur J Pharmacol 309:1-11 (1996).
12. Heible JP, Byland DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minnemen KP & Ruffulo RR: Pharmacol Rev 47:267-270(1995).
13. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM,Parry-Smith DJ, Peter B & Bailey DS: J Pharmacol Exp Ther 272:134-42 (1995).
14. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L & Sandrasagra A: Eur J Pharmacol 317:417-23 (1996).
15. Maniatis T, Fritsch EF & Sambrook J: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory (1982).
16. Morrow AL & Creese I: Mol Pharmacol 29:321-330 (1986).
17. Cunningham DM, Brooks KM & Vargas HM: Pharmacologist 39:44(1997).
18. Sleight AJ, Koek W & Bigg DCH: Eur J Pharmacol 238:407-410 (1993).
19. Burt RP, Chappie CR & Marshall I: Brit J Pharmacol 115:467-475 (1995).